nerandomilast   Click here for help

GtoPdb Ligand ID: 12518

Synonyms: BI 1015550 | BI-1015550 | BI1015550
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BI-1015550 is a PDE4B inhibitor [1]. It is an orally bioavailable compound, and clinical lead for the treatment of idiopathic pulmonary fibrosis. Its chemical structure matches the INN nerandomilast from proposed INN list 129 (August 2023).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 121.22
Molecular weight 448.97
XLogP -0.93
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CC(C1)(CO)NC2=C3C(=NC(=N2)N4CCC(CC4)C5=NC=C(C=N5)Cl)CC[S@]3=O
Isomeric SMILES OCC1(CCC1)NC2=NC(=NC3=C2[S@](=O)CC3)N4CCC(CC4)C5=NC=C(Cl)C=N5
InChI InChI=1S/C20H25ClN6O2S/c21-14-10-22-17(23-11-14)13-2-7-27(8-3-13)19-24-15-4-9-30(29)16(15)18(25-19)26-20(12-28)5-1-6-20/h10-11,13,28H,1-9,12H2,(H,24,25,26)/t30-/m1/s1
InChI Key UHYCLWAANUGUMN-SSEXGKCCSA-N
No information available.
Summary of Clinical Use Click here for help
BI-1015550 has reached phase 3 clinical trial to determine efficacy in interstitial lung diseases such as idiopathic pulmonary fibrosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05321069 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) Phase 3 Interventional Boehringer Ingelheim
NCT05321082 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Phase 3 Interventional Boehringer Ingelheim